microbiota, PD-L1, pseudo-progression, RECIST, local and peripheral immune response
Abstract
Immunotherapy is already a mainstay in treating melanoma, lung cancer and renal cancer and shows compelling promise in many different tumors. However, responses to immunotherapy may be present despite apparent initial progression of the tumor. This underlines the importance of defining accurate tumor assessments and response criteria for immunotherapy. The RECIST criteria have therefore been modified to adhere to requirements of immunotherapy. In line with that, this review will focus on the current imaging tools, the statistical evaluations in clinical trials and the biological analysis of the tumor microenvironment that will in the future effectively guide treatment decisions in everyday clinical practice.